CVSI 007

Drug Profile

CVSI 007

Alternative Names: Cannabidiol - CV Sciences; CVSI-007

Latest Information Update: 10 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CanX
  • Developer CV Sciences
  • Class Analgesics; Cannabinoids; Small molecules
  • Mechanism of Action Cannabinoid receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Smoking withdrawal

Most Recent Events

  • 01 Aug 2018 CV Sciences intends to file an IND application for Smoking withdrawal under 505(b)2 pathway in 2019
  • 31 Mar 2017 CV Sciences has patents pending for CVSI 007 in USA (CV Sciences 10-K filed in March 2017)
  • 02 Nov 2016 Preclinical trials in Smoking withdrawal in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top